J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knight, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knight, M
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Adverse drug reactions in neonates

M Knight

Adverse drug reactions (ADR) are uncommon causes of admission of neonates to the neonatal intensive care unit. The neonate, however, is potentially at significant risk for adverse drug reactions because of underdeveloped mechanisms and systems for handling drugs (the Gray Baby Syndrome with chloramphenicol as a classic example), the fact that infants in neonatal intensive care units are often critically ill with multiple organ system dysfunction, that they may be on multiple drugs, and that they may present with an adverse drug reaction as a result of exposure while still a fetus. There is also a history of misadventures in the neonatal intensive care unit and newborn nurseries due to exposure to antibacterial agents that produced systemic effects from percutaneous absorption. In this review, an overview of the mechanisms of adverse drug reactions will be presented, followed by a general review of the experience of adverse drug reactions in neonates and some specific examples of current adverse drug reactions and a suggested approach for the prevention and evaluation of adverse drug reactions in neonates.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
J. N. van den Anker
Timing of Dose-Finding Studies: Before or After Completion of a Randomized Clinical Trial?
Pediatrics, September 1, 2007; 120(3): 691 - 692.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
I. Warrier, W. Du, G. Natarajan, V. Salari, and J. Aranda
Patterns of drug utilization in a neonatal intensive care unit.
J. Clin. Pharmacol., April 1, 2006; 46(4): 449 - 455.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. P. Giacoia, D. L. Birenbaum, H. C. Sachs, and D. R. Mattison
The newborn drug development initiative.
Pediatrics, March 1, 2006; 117(3 Pt 2): S1 - S8.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
F. Fattahi, Z. Pourpak, M. Moin, A. Kazemnejad, G. T. Khotaei, S. Mamishi, A. Siadati, and P. Tabatabaei
Adverse Drug Reactions in Hospitalized Children in a Department of Infectious Diseases
J. Clin. Pharmacol., November 1, 2005; 45(11): 1313 - 1318.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American College of Clinical Pharmacology